Kristian Hillert Winther1, Enrico Papini2, Roberto Attanasio3, Roberto Negro4, Laszlo Hegedüs1. 1. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark. 2. Department of Endocrinology and Metabolism, Ospedale Regina Apostolorum, Rome, Italy. 3. Endocrine Unit, IRCCS Galeazzi Institute, Milan, Italy. 4. Division of Endocrinology, V. Fazzi Hospital, Lecce, Italy.
Abstract
OBJECTIVE: To investigate clinical practice regarding the use of selenium supplementation in patients with Hashimoto's thyroiditis (HT) among members of the European Thyroid Association (ETA). METHODS: ETA members were invited to participate in an online survey investigating the use of selenium supplementation across the spectrum of benign thyroid diseases. Of 872 invited members, 242 (28%) completed the survey. After exclusion of basic scientists and non-European members, survey data from 212 respondents were eligible for further analyses. Responses from 65 (31%) individuals who did not at all recommend selenium, or only considered its use in the setting of a clinical trial, were not included in the final analysis of survey data from 147 respondents. RESULTS: While only a minority of respondents (29 of 147, 20%) stated that the available evidence warrants the use of Se in patients with HT, a statistically significant majority (95 of 147; 65%, p < 0.001) used Se occasionally or routinely. Se was predominantly recommended for patients with HT not receiving LT4 (102 of 147; 69%) to reduce circulating thyroid autoantibody levels. Very few respondents routinely recommended Se to pregnant patients with HT. CONCLUSIONS: A minority of responding ETA members stated that the available evidence warrants the use of Se in HT, but a majority recommended it to some extent, especially to patients not yet receiving LT4. This is questionable, and selenium is not recommended to patients with HT according to current ETA guidelines. Ongoing and future trials may lead to the reversal of current medical practice.
OBJECTIVE: To investigate clinical practice regarding the use of selenium supplementation in patients with Hashimoto's thyroiditis (HT) among members of the European Thyroid Association (ETA). METHODS: ETA members were invited to participate in an online survey investigating the use of selenium supplementation across the spectrum of benign thyroid diseases. Of 872 invited members, 242 (28%) completed the survey. After exclusion of basic scientists and non-European members, survey data from 212 respondents were eligible for further analyses. Responses from 65 (31%) individuals who did not at all recommend selenium, or only considered its use in the setting of a clinical trial, were not included in the final analysis of survey data from 147 respondents. RESULTS: While only a minority of respondents (29 of 147, 20%) stated that the available evidence warrants the use of Se in patients with HT, a statistically significant majority (95 of 147; 65%, p < 0.001) used Se occasionally or routinely. Se was predominantly recommended for patients with HT not receiving LT4 (102 of 147; 69%) to reduce circulating thyroid autoantibody levels. Very few respondents routinely recommended Se to pregnant patients with HT. CONCLUSIONS: A minority of responding ETA members stated that the available evidence warrants the use of Se in HT, but a majority recommended it to some extent, especially to patients not yet receiving LT4. This is questionable, and selenium is not recommended to patients with HT according to current ETA guidelines. Ongoing and future trials may lead to the reversal of current medical practice.
Authors: Jinyuan Mao; Victor J Pop; Sarah C Bath; Huib L Vader; Christopher W G Redman; Margaret P Rayman Journal: Eur J Nutr Date: 2014-12-19 Impact factor: 5.614
Authors: Aniceta A Mikulska; Marta Karaźniewicz-Łada; Dorota Filipowicz; Marek Ruchała; Franciszek K Główka Journal: Int J Mol Sci Date: 2022-06-13 Impact factor: 6.208
Authors: Maria-Cristina Burlacu; Roberto Attanasio; Laszlo Hegedüs; Endre V Nagy; Enrico Papini; Petros Perros; Kiswendsida Sawadogo; Marie Bex; Bernard Corvilain; Chantal Daumerie; Brigitte Decallonne; Damien Gruson; Bruno Lapauw; Rodrigo Moreno Reyes; Patrick Petrossians; Kris Poppe; Annick Van den Bruel; David Unuane Journal: Thyroid Res Date: 2022-03-05